Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mometasone furoate/formoterol combination · 2 trials · 1 indication
FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.
Endpoint was the last post-baseline non-missing result through Week 13 carried forward.
| Arm | Type | Description |
|---|---|---|
| MF/F MDI 400/10 mcg BID | EXPERIMENTAL | - |
| MF/F MDI 200/10 mcg BID | EXPERIMENTAL | - |
| MF MDI 400 mcg BID | EXPERIMENTAL | - |
| Formoterol MDI 10 mcg BID | ACTIVE_COMPARATOR | - |
| Placebo MDI BID | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Mometasone furoate/formoterol (MF/F) combination | DRUG | MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks |
| Mometasone furoate MDI (MF MDI) | DRUG | MF 400 mcg via metered dose inhaler twice daily for 52 weeks |
| Formoterol MDI | DRUG | Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks |
| Placebo | DRUG | Placebo MDI twice a day for 26 weeks |
Inclusion Criteria: * Moderate to severe COPD based on prebronchodilator FEV1/forced vital capacity (FVC) ratio of \<=70%. * At Screening, postbronchodilator FEV1 must be \<=60% predicted normal \& \>=25% predicted normal. * COPD symptoms for \>=24 months. * Ex- or current smoker with smoking histo...
Mometasone Furoate is a small molecule being developed for allergic rhinitis, asthma, seasonal allergic rhinitis, perennial allergic rhinitis, chronic obstructive pulmonary disease (COPD), and adenoids hypertrophy. It is administered as a nasal spray and is currently in Phase 3 clinical development for these ENT-related conditions.
Mometasone Furoate is being developed by Organon & Co., a company traded on the New York Stock Exchange under the ticker symbol OGN. The company is conducting Phase 3 clinical trials to evaluate the drug's safety and efficacy in treating allergic rhinitis and related respiratory conditions.
Mometasone Furoate is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Four Phase 3 trials have been completed, with a total enrollment of 2,251 participants, all of which were randomized, double-blind, and placebo-controlled.
Mometasone Furoate has completed four Phase 3 trials: NCT00599027 in patients with allergic rhinitis and intermittent asthma, NCT00732381 and NCT00733005 in seasonal allergic rhinitis, and NCT03855228 evaluating the addition of loratadine in seasonal allergic rhinitis. All trials are completed with no active trials currently ongoing.
Mometasone Furoate is a corticosteroid that works by reducing inflammation in the nasal passages. It is administered as a nasal spray to relieve symptoms associated with allergic rhinitis, including nasal congestion. The drug targets inflammatory pathways to provide relief from allergy symptoms.